A Patent Waiver Is Not a Silver Bullet in the Pursuit of Vaccine Equity
The low level of Covid-19 vaccination in the Global South is ethically unacceptable and risks prolonging the pandemic. The patent waiver will not solve these vaccination bottlenecks in the short-term. Instead, additional measures should be adopted to accelerate local manufacturing and distribution of vaccines in low- and middle-income countries (LMICs), ramp up investment in vaccination campaigns, and facilitate the compulsory licensing of patents and transfer of know-how.

